A carregar...
Effectiveness of ivacaftor in cystic fibrosis Patients with non-G551D gating mutations
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator ivacaftor is approved for patients with CF with gating and residual function CFTR mutations. We report the results of an observational study investigating its effects in CF patients with non-G551D gating mutations...
Na minha lista:
| Publicado no: | J Cyst Fibros |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6196121/ https://ncbi.nlm.nih.gov/pubmed/29685811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2018.04.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|